Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Spigel

Showing results (21-30 of 220) with videos related to

Pageof 22
Sort By:
Molecular Diagnosis & Therapy|March 12, 2015
Poorly differentiated neoplasms of unknown primary site: diagnostic usefulness of a molecular cancer classifier assayF Anthony Greco, Wayne J Lennington, David R Spigel, et al.
JCO Oncology Practice|March 10, 2021
Improving Care for Patients With Stage III or IV NSCLC: Learnings for Multidisciplinary Teams From the ACCC National Quality SurveyRavi Salgia, Leigh M Boehmer, Catherine Celestin, et al.
Clinical Lung Cancer|February 9, 2013
Efficacy and safety of oral topotecan and bevacizumab combination as second-line treatment for relapsed small-cell lung cancer: an open-label multicenter single-arm phase II studyDavid R Spigel, David M Waterhouse, Steve Lane, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 23, 2013
Reply to M.-E. Percival et al and L.B. SaltzJohn D Hainsworth, David R Spigel, Mark S Rubin, et al.
Clinical Advances in Hematology & Oncology : H&O|January 19, 2012
A phase I trial of vatalanib (PTK/ZK) in combination with bevacizumab in patients with refractory and/or advanced malignanciesSuzanne F Jones, David R Spigel, Denise A Yardley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2010
Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinomaJohn D Hainsworth, David R Spigel, Howard A Burris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2005
Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinibJohn D Hainsworth, Jeffrey A Sosman, David R Spigel, et al.
Clinical Genitourinary Cancer|May 30, 2006
Weekly docetaxel/estramustine phosphate in patients with increasing serum prostate- specific antigen levels after primary treatment for prostate cancer: a phase II trial of the Minnie Pearl Cancer Research NetworkJohn D Hainsworth, Anthony A Meluch, David R Spigel, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 4, 2010
Phase II trial of vinflunine in relapsed small cell lung cancerDavid R Spigel, John D Hainsworth, Cassie M Lane, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2007
Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research NetworkJohn D Hainsworth, David R Spigel, Cindy Farley, et al.
Pageof 22

Showing results (21-30 of 220) with videos related to

Sort By:
Pageof 22
Molecular Diagnosis & Therapy|March 12, 2015
Poorly differentiated neoplasms of unknown primary site: diagnostic usefulness of a molecular cancer classifier assayF Anthony Greco, Wayne J Lennington, David R Spigel, et al.
JCO Oncology Practice|March 10, 2021
Improving Care for Patients With Stage III or IV NSCLC: Learnings for Multidisciplinary Teams From the ACCC National Quality SurveyRavi Salgia, Leigh M Boehmer, Catherine Celestin, et al.
Clinical Lung Cancer|February 9, 2013
Efficacy and safety of oral topotecan and bevacizumab combination as second-line treatment for relapsed small-cell lung cancer: an open-label multicenter single-arm phase II studyDavid R Spigel, David M Waterhouse, Steve Lane, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 23, 2013
Reply to M.-E. Percival et al and L.B. SaltzJohn D Hainsworth, David R Spigel, Mark S Rubin, et al.
Clinical Advances in Hematology & Oncology : H&O|January 19, 2012
A phase I trial of vatalanib (PTK/ZK) in combination with bevacizumab in patients with refractory and/or advanced malignanciesSuzanne F Jones, David R Spigel, Denise A Yardley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2010
Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinomaJohn D Hainsworth, David R Spigel, Howard A Burris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2005
Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinibJohn D Hainsworth, Jeffrey A Sosman, David R Spigel, et al.
Clinical Genitourinary Cancer|May 30, 2006
Weekly docetaxel/estramustine phosphate in patients with increasing serum prostate- specific antigen levels after primary treatment for prostate cancer: a phase II trial of the Minnie Pearl Cancer Research NetworkJohn D Hainsworth, Anthony A Meluch, David R Spigel, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 4, 2010
Phase II trial of vinflunine in relapsed small cell lung cancerDavid R Spigel, John D Hainsworth, Cassie M Lane, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2007
Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research NetworkJohn D Hainsworth, David R Spigel, Cindy Farley, et al.
Pageof 22